Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies...

Full description

Bibliographic Details
Main Authors: Avet-Loiseau, H. (Author), Bahlis, N.J (Author), Cavo, M. (Author), Dimopoulos, M.A (Author), Facon, T. (Author), Heuck, C. (Author), Hungria, V. (Author), Iida, S. (Author), Kobos, R. (Author), Krevvata, M. (Author), Kumar, S. (Author), Mateos, M.-V (Author), Moreau, P. (Author), Munshi, N. (Author), Paiva, B. (Author), Perrot, A. (Author), Plesner, T. (Author), Qi, M. (Author), San-Miguel, J. (Author), Sonneveld, P. (Author), Spencer, A. (Author), Sun, S. (Author), Ukropec, J. (Author), Usmani, S.Z (Author), van de Donk, N.W.C.J (Author), Wang, J. (Author), Weisel, K. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
aged
Aged
Antibodies, Monoclonal
antineoplastic agent
Antineoplastic Combined Chemotherapy Protocols
Article
bortezomib
cancer growth
cancer mortality
cancer prognosis
clinical trial
controlled study
daratumumab
dexamethasone
disease exacerbation
disease free survival
Disease-Free Survival
follow up
hazard ratio
high throughput sequencing
human
human cell
Humans
lenalidomide
major clinical study
melphalan
minimal residual disease
monoclonal antibody
multicenter study
multiple myeloma
Multiple Myeloma
Neoplasm Recurrence, Local
Neoplasm, Residual
phase 3 clinical trial
prednisone
prognosis
Prognosis
progression free survival
Progression-Free Survival
proportional hazards model
randomized controlled trial
randomized controlled trial (topic)
treatment outcome
Treatment Outcome
tumor recurrence
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items